IMMUNABS
3.8.2022 16:02:08 CEST | Business Wire | Press release
ImmunAbs Inc. (www.immunabs.com ) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.
ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoimmune diseases, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH). The complement inhibitors drug market showed its growth potential by achieving an average annual growth rate of 20.7% and a market size of USD $ 5.1 billion in 2020 and is expected to grow to USD $19 billion by 2027.
Paroxysmal nocturnal hemoglobinuria is one example of complement-mediated autoimmune diseases where the membrane proteins protecting the red blood cells from complement activation are lost due to mutations, which results in red blood cells being destructed by the complements. Due to insufficient inhibition of complements shown by currently approved complement inhibitors, SolirisⓇ and UltomirisⓇ , patients who receive these drugs still suffer from the residual symptoms of PNH, which include anaemia, fatigue, and decreased productivity at work.
ImmunAbs’ new complement therapeutic IM-101 targets the safest and most potent component of the complement system, complement C5. IM-101 has been shown to completely inhibit complement activation, and thus is expected to alleviate the symptoms that persist with the standard of care. ImmunAbs will initiate a phase 2a clinical trial in the United States in 2024.
“This is a historical milestone for ImmunAbs.” said Dr. DongJo Kim, the company’s CEO. “We are delighted to see IM-101’s efficacy in humans which has been proven in our ex vivo study. We hope that our IM-101 will reach patients who may suffer from symptoms that persist due to insufficient complement inhibition by the current treatments.”
About ImmunAbs Inc.
ImmunAbs Inc. was established in 2017 by experts of global standard antibody therapeutics development. The vision is "Hope for Patients, Dreams for All." Currently, ImmunAbs has several antibody therapeutics in global standard development for autoimmune diseases, diabetic retinopathy, and metabolic syndrome. ImmunAbs successfully raised KRW 18.1 billion from Seed to series A funding in 2021 and got a non-clinical study national grant for developing IM-101 from Korea Drug Development Fund in November last year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005380/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Belkin Introduces a New Accessory Collection for Samsung Galaxy S26 Series25.2.2026 19:00:00 CET | Press release
Including five ‘Designed for Samsung’ accessories plus more, the collection is engineered and optimized specifically for the Samsung Galaxy S26 seriesFrom fast Qi2 25W charging to Nano-Titan–enhanced screen protection, each product is engineered for everyday performance and durabilityThe lineup reinforces Belkin’s role as a trusted partner for next-generation Galaxy devices Belkin, a leading consumer electronics brand for over 40 years, today announced a new collection of accessories designed and optimized specifically for the Samsung Galaxy S26 series. From fast, reliable Qi2 25W charging to advanced screen protection engineered for ultrasonic fingerprint sensors and next-generation displays, every product in the collection is designed to meet the demands of Galaxy S26 users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225459906/en/ Belkin Introduces a New Accessory Collection for Samsung Galaxy S26 Series ‘Designed f
Andersen Consulting udvider sine kompetencer med Assure Consulting25.2.2026 18:58:00 CET | Pressemeddelelse
Andersen Consulting styrker sin platform med tilføjelsen af samarbejdspartneren Assure Consulting, et tysk managementkonsulentfirma med speciale i projektledelse og projektporteføljestyring. Assure Consulting blev grundlagt i 2003 og hjælper organisationer med at gennemføre komplekse projekter og transformationer. Firmaet hjælper kunder med at etablere og drive projektkontorer (PMO'er), styrke governance og porteføljestyring samt anvende klassiske, agile eller hybride projektledelsesmetoder, der er skræddersyet til deres behov. Assure Consulting yder også praktisk støtte til udrulning af store systemer og processer, integreret forandringsledelse i forbindelse med organisatoriske og kulturelle transformationer samt coaching- og træningsprogrammer, der er i overensstemmelse med internationalt anerkendte standarder for projektledelse, med henblik på at opbygge bæredygtige kompetencer i kundernes organisationer. "Dette samarbejde giver os mulighed for at skalere vores ekspertise inden for
OLX Launches Agentic AI Products to Transform Property Search and Car Sales at CLAIM AI in Lisbon25.2.2026 15:33:00 CET | Press release
OLX launches CompassGPT and AutoIQ, making OLX the leading verticalised platform scaling Agentic AI across the entire value chain - supporting millions of buyers while simultaneously empowering professional customers. The Agentic Products were unveiled at CLAIM AI in Lisbon, OLX’s premier flagship event, bringing together industry leaders to showcase practical, powerful AI innovation OLX’s leading investments and application of proprietary AI deliver faster, smarter, and more user-centric marketplace experiences, with more than 75 AI use cases already in the market, including 10 agentic AI use cases launched in H126 OLX Group, the largest and fastest growing platform for vertical transactions in Europe and South Africa, today unveiled two new Agentic AI-powered products at CLAIM AI, its invite-only Lisbon conference for marketplace innovators. Launching in key OLX markets, CompassGPT introduces a conversational assistant to real estate search, while AutoIQ provides dealers with automot
KleanNara Partners with Rimini Street to Accelerate Digital Transformation25.2.2026 15:00:00 CET | Press release
South Korea’s leading paper manufacturer cuts SAP ECC 6 and Oracle Database maintenance costs with Rimini Support™, freeing up funds and team focus for AI-driven innovation and growth Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced KleanNara has selected Rimini Street to provide support for its SAP ECC 6 and Oracle Database systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225123422/en/ KleanNara Partners with Rimini Street to Accelerate Digital Transformation Founded in 1966, KleanNara is one of South Korea’s leading manufacturers of paper and hygiene products. Holding a 25% share of the white cardboard market, the company is known for its commitment to quality, sustainability and innovation, and continues to expand globally with a focus on ESG-driven, eco-friendly products. Breaki
Axinn Adds Three Seasoned Antitrust Litigators, Reinforcing Trial Bench and West Coast Presence25.2.2026 15:00:00 CET | Press release
Hires Position Firm to Meet Rising Client Demand as Antitrust Enforcement Intensifies Axinn, Veltrop & Harkrider LLP announced today that Daniel Matheson, Katrina Rouse, and Jimmy Moore have joined its Antitrust practice as partners. Matheson arrives from the Federal Trade Commission (FTC), while Rouse and Moore join from the U.S. Department of Justice (DOJ) Antitrust Division. Rouse will join Axinn’s San Francisco office; Matheson and Moore will join the firm’s Washington, DC office. The additions strengthen Axinn's trial bench and West Coast practice as the firm continues to attract top antitrust talent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225403123/en/ Daniel Matheson (Left), Katrina Rouse (Center), and Jimmy Moore (Right) have joined Axinn, Veltrop & Harkrider's LLP Antitrust practice as partners. “Axinn continues to invest in top-tier talent and trial capabilities as we deepen our commitment to clients and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom